Symbol="ITOS"
AssetType="Common Stock"
Name="Iteos TherapeuticsÂ Inc"
Description="Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of immuno-oncology therapies for patients. The company is headquartered in Cambridge, Massachusetts."
CIK="1808865"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="139 MAIN STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="456702000"
EBITDA="-17311000"
PERatio="42.57"
PEGRatio="None"
BookValue="18.24"
DividendPerShare="0"
DividendYield="0"
EPS="0.3"
RevenuePerShareTTM="3.586"
ProfitMargin="0.0902"
OperatingMarginTTM="-0.142"
ReturnOnAssetsTTM="-0.0144"
ReturnOnEquityTTM="0.018"
RevenueTTM="127703000"
GrossProfitTTM="267630000"
DilutedEPSTTM="0.3"
QuarterlyEarningsGrowthYOY="-0.886"
QuarterlyRevenueGrowthYOY="-0.917"
AnalystTargetPrice="42.25"
TrailingPE="42.57"
ForwardPE="12.56"
PriceToSalesRatioTTM="1.681"
PriceToBookRatio="1.187"
EVToRevenue="0.0111"
EVToEBITDA="0.0154"
Beta="1.161"
num_52WeekHigh="28.05"
num_52WeekLow="12.52"
num_50DayMovingAverage="14.38"
num_200DayMovingAverage="17.29"
SharesOutstanding="35763700"
DividendDate="None"
ExDividendDate="None"
symbol="ITOS"
open="12.77"
high="13.25"
low="12.76"
price="13.25"
volume="172370.00"
latest_trading_day="2023-07-07"
previous_close="12.77"
change="0.48"
change_percent="3.7588%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="66"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="34"
Volume_recent_avg="284670"
Change_recent_avg="-0.08"
Delta_recent_avg="0.76"
Variance_recent_avg="0.38"
Change_ratio_recent_avg="-0.58"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="34"
Aroon_momentum_negative="66"
image_negative_thumbnail_id_1="1136"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0169.jpeg"
image_negative_thumbnail_id_2="491"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0114.jpeg"
image_neutral_thumbnail_id_1="570"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0029.jpeg"
image_neutral_thumbnail_id_2="539"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0060.jpeg"
image_positive_thumbnail_id_1="948"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0110.jpeg"
image_positive_thumbnail_id_2="627"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0081.jpeg"
image_professor_thumbnail_id_1="1203"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
image_professor_thumbnail_id_2="1169"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
